Opsens Inc. (TSE:OPS) to Post Q1 2023 Earnings of $0.01 Per Share, Raymond James Forecasts

Opsens Inc. (TSE:OPS) – Raymond James issued their Q1 2023 EPS estimates for shares of Opsens in a research report issued to clients and investors on Tuesday, January 11th. Raymond James analyst R. Sarugaser anticipates that the company will post earnings per share of $0.01 for the quarter. Raymond James currently has a “Strong-Buy” rating and a $6.00 target price on the stock. Raymond James also issued estimates for Opsens’ Q2 2023 earnings at $0.01 EPS, Q3 2023 earnings at $0.01 EPS, Q4 2023 earnings at $0.01 EPS, FY2024 earnings at $0.09 EPS, FY2025 earnings at $0.14 EPS and FY2026 earnings at $0.17 EPS.

Separately, Royal Bank of Canada lifted their target price on shares of Opsens to C$4.00 and gave the company an “outperform” rating in a research note on Tuesday, January 4th.

Shares of OPS opened at C$2.35 on Thursday. The firm’s 50-day moving average price is C$3.20 and its 200-day moving average price is C$2.85. The firm has a market capitalization of C$253.75 million and a price-to-earnings ratio of -195.83. The company has a current ratio of 6.73, a quick ratio of 5.82 and a debt-to-equity ratio of 28.62. Opsens has a 1-year low of C$1.45 and a 1-year high of C$3.74.

About Opsens

Opsens Inc develops, manufactures, installs, and sells fiber optic sensors for interventional cardiology, fractional flow reserve (FFR), oil and gas, and industrial applications. The company operates in two segments, Medical and Industrial. The Medical segment primarily focuses on physiological measurement, such as FFR and dPR in the coronary artery stenosis market; and supplies a range of miniature optical sensors to measure pressure and temperature used in integrated applications in other medical devices, as well as licenses its optical sensor technology.

See Also: Fiduciary

Earnings History and Estimates for Opsens (TSE:OPS)

Receive News & Ratings for Opsens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opsens and related companies with MarketBeat.com's FREE daily email newsletter.